Table 3 Assessment of heterogeneity for direct comparisons and comparison of outcomes between pair-wise meta-analysis and network meta-analysis
Treatment comparisons | Results of pair-wise meta-analysis | I2(%) | Results of network meta-analysis |
|---|---|---|---|
Bezafibrate + UDCA/UDCA | 142.52(72.09, 212.96) | 75.7% | 104.49 (60.41, 161.92) |
Fenofibrate + UDCA/UDCA | 79.18(63.05, 95.30) | 92.4% | 87.81 (52.34, 129.79) |
Bezafibrate + UDCA/fenofibrate + UDCA | 72.2(− 5.33, 149.73) | NA | 15.76 (− 36.77, 80.70) |
Budesonide + UDCA/UDCA | 86(− 4.09, 176.09) | NA | 84.59 (− 39.94, 210.26) |
OCA 10 mg + UDCA/UDCA | 66.45(39.51, 93.39) | 70.5% | 65.21 (8.99, 121.80) |
OCA 25 mg + UDCA/UDCA | 64.24(55.44, 73.04) | NA | NA |
OCA 50 mg + UDCA/UDCA | 51.99(45.09, 58.89) | NA | NA |
OCA 10 mg + UDCA/OCA 25 mg + UDCA | 1.84(− 12.53, 16.21) | NA | NA |
OCA 10 mg + UDCA/OCA 50 mg + UDCA | 10.41 (− 2.88, 23.7) | NA | NA |
OCA 25 mg + UDCA/OCA 50 mg + UDCA | 12.25 (1.16, 23.34) | NA | NA |
Aldafermin 0.3 mg + UDCA/UDCA | 54.3(12.46, 96.14) | NA | NA |
Aldafermin 3 mg + UDCA/UDCA | 69.3(24.02, 114.58) | NA | 69.72 (− 33.18, 170.67) |
Aldafermin 0.3 mg + UDCA/NGM282 3mg + UDCA |  − 15 (− 61.05, 31.05) | NA | NA |
Saroglitazar 2 mg + UDCA/UDCA | 131.56(7.81,256.92) | NA | 132.09 (13.99, 247.04) |
Saroglitazar 4 mg + UDCA/UDCA | 151.58 (144.01, 159.15) | NA | NA |
Saroglitazar 2 mg + UDCA/Saroglitazar 4 mg + UDCA |  − 9.12(− 17.4, − 0.84,) | NA | NA |
Elafibranor 80 mg + UDCA/UDCA | 142.99(77.38, 208.59) | 93.1% | 140.73 (74.34, 209.98) |
Elafibranor 120 mg + UDCA/UDCA | 116.6 (84.46, 148.74) | NA | NA |
Elafibranor 80 mg + UDCA/Elafibranor 120 mg + UDCA | 62.2(27.15,97.25) | NA | NA |
Seladelpar 5 mg + UDCA/UDCA | 92.85(61.76,123.94) | NA | NA |
Seladelpar 10 mg + UDCA/UDCA | 117.67(85.86,149.48) | NA | 117.39 (19.97, 213.95) |
Seladelpar 5 mg + UDCA/Seladelpar 10 mg + UDCA |  − 24.82(− 56.16, 6.52) | NA | NA |